<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617772</url>
  </required_header>
  <id_info>
    <org_study_id>DDRI/90.10</org_study_id>
    <nct_id>NCT01617772</nct_id>
  </id_info>
  <brief_title>Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis</brief_title>
  <acronym>NALCAT</acronym>
  <official_title>Comparison the Effectiveness of L-Carnitine With Atorvastatin in Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to compare the effects of simvastatin and L-carnitine
      coadministration versus simvastatin, L-Carnitine monotherapy on liver enzymes ( AST,ALT )
      and liver elasticity in NASH patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from
      steatosis to steatohepatitis (nonalcoholic steatohepatitis, NASH) to cirrhosis. Statins are
      competitive inhibitors of HMG CoA reductase, the rate-limiting step in cholesterol
      biosynthesis. They occupy a portion of the binding site of HMG CoA, blocking access of this
      substrate to the active site on the enzyme. A reduction in intrahepatic cholesterol leads to
      an increase in LDL receptor turnover that results from an enhanced rate of hepatic LDL
      receptor cycling. On the other hand recent studies have implicated several important
      cellular processes and signaling pathways that are affected by abnormal lipid metabolism,
      resulting in specific biochemical, histological, and clinical changes associated with NAFLD.

      Maybe statins, as lipid lowering agents, and through their effect in reduction of
      intrahepatic cholesterol, can affect the abnormal lipid metabolism in NASH.

      L- carnitine, can improve the outcome of NASH, because it reduces lipid levels, limits
      oxidative stress, and modulates inflammatory responses . It performs a number of essential
      intracellular and metabolic functions, such as fatty acid transport, detoxification of
      potentially toxic metabolites, regulation of the mitochondrial acyl-Co A / CoA ratio, and
      stabilization of cell membranes. It has a pivotal role in the transport of long chain fatty
      acids across the inner mitochondrial membrane.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in liver stiffness</measure>
    <time_frame>2 years</time_frame>
    <description>As measured by Fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in liver enzyme levels</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg atorvastatin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg L-carnitine daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atoral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg L-carnitine and 20mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identically looking placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20 mg</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Atoral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Carnitine</intervention_name>
    <description>1000mg L-carnitine</description>
    <arm_group_label>Carnitine</arm_group_label>
    <arm_group_label>Atoral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identically looking placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NASH diagnosed on the basis of the following criteria:

               1. Imaging techniques showing evidence of hepatic steatosis

               2. Increased ALT above 1.5 times normal (normal: 20 IU/L for women, 30 for men) on
                  two occasions three months apart.

        Exclusion Criteria:

          -  Patients with hepatitis B or C

          -  ALT &gt; 300 IU/L

          -  Participants presenting one or more causes commonly associated with secondary NAFLD
             (drugs, surgical procedures, environmental toxins, or total parenteral nutrition)

          -  Alcohol ingestion greater than 40 gr per week

          -  Abnormal Lipid profile (TG&gt;500 , LDL&gt;160)

          -  Patients with hypertension, diabetes mellitus, coronary heart disease

          -  Fibroscan score more than 7.9 kp

          -  pregnancy, lactation

          -  Drug addiction

          -  Reynolds Risk Score &gt; 10%

          -  Not consenting to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahin Merat, Professor</last_name>
    <phone>+98 917 117 3966</phone>
    <email>merat@tums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reza Malekzadeh, Professor</last_name>
    <phone>+98 912 111 4139</phone>
    <email>malek@ams.ac.ir</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pars Cohort Center</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masoud Clinic</name>
      <address>
        <city>Tehran</city>
        <zip>14117</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahin Merat</last_name>
      <phone>+989171173966</phone>
      <email>shahin.merat@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 3, 2015</lastchanged_date>
  <firstreceived_date>June 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-alcoholic steatohepatitis, Atorvastatin, L-Carnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
